Le Lézard
Classified in: Health, Business
Subject: TNM

Adfinitas Health Acquires Advanced Inpatient Medicine


HANOVER, Md., Jan. 8, 2018 /PRNewswire/ -- Adfinitas Health, the largest private hospitalist group in the Mid-Atlantic region, today announced its acquisition of a majority interest in Advanced Inpatient Medicine (AIM). Based in northeastern Pennsylvania, AIM is a regional private hospitalist group that serves four hospitals and several long-term acute care and skilled nursing facilities. The company and its nearly 40 employees will become part of Adfinitas Health, which currently partners with 14 hospitals and more than 40 post-acute facilities in Maryland, Virginia, and Michigan. Financial terms of the acquisition are not being disclosed.

Adfinitas Health, formerly Physician Inpatient Care Specialists (MDICS).

Founded in 2006 by Louis O'Boyle, DO, AIM's business model focuses on quality and performance improvement while providing cost-effective services. Similar to Adfinitas Health, Dr. O'Boyle has focused his practice on two key objectives: high-quality, cost-effective patient care; and significant integration of nurse practitioners and physician assistants (commonly referred to collectively as Advanced Practice Providers, or APPs) into care teams. APPs practice at the top of their licenses under the supervision of a physician. Dr. O'Boyle and his team have succeeded in improving key quality metrics and driving cost savings over time, due in large part to the success of the clinically integrated staffing model also used by Adfinitas.

"We are very impressed with the caliber of the company and the staff that Dr. O'Boyle has assembled. AIM's providers are as devoted to patient-centered care as our own; they are hard-working and support one another as a team," said Eric Nass, President of Adfinitas Health. "That collaborative approach truly aligns with the core values that Adfinitas Health was founded on. Finding so much common ground with Dr. O'Boyle and the AIM team made this decision the right one for both entities. We're thrilled to be growing our footprint in northeastern Pennsylvania and look forward to bringing our capabilities and infrastructure to AIM's partner hospitals and building on their accomplishments."

"I am delighted that AIM is becoming part of Adfinitas Health ? a company that firmly shares our values and approach to care," said Dr. O'Boyle. "We have synergies in many areas of the business, but the mindset around teamwork, quality, and building partnerships with clients is what makes me feel confident and excited about this deal. When I first met Drs. Davis and Mitchell, Adfinitas Health's co-founders, I quickly understood that we shared that philosophy, and I'm looking forward to what we'll be able to accomplish together in this market."

Dr. O'Boyle will remain as a minority owner of AIM.

About Adfinitas Health

Adfinitas Health is the trusted partner of more than 50 healthcare systems, hospitals, and post-acute care centers in the Mid-Atlantic region. Founded in 2007, Adfinitas Health is a physician-owned and managed company that provides high-quality, cost-effective integrated medical services across the full continuum of care. Our unique integrated staffing model, unwavering commitment to client satisfaction, and focus on improving outcomes, creates opportunities to transform patient care and drive value. For more information, please visit AdfinitasHealth.com.  

SOURCE Adfinitas Health


These press releases may also interest you

at 06:50
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZtm (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis...

at 06:08
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...

at 06:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...

at 06:00
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance -- 2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...

at 06:00
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...

at 05:12
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...



News published on and distributed by: